An interventional study to access the effect of Ayurvedic medicine in positive cases of COVID-19.

Assessment of efficacy and safety of Ayurvedic drug combination in preventing the progression of severity of the disease in asymptomatic and mild symptomatic cases of COVID-19: A randomised controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027040

Enrollment

200

Registered

2020-08-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: MSL: Mahasudarshan Ghana vati - 500 mg thrice daily after meal Samsamani vati - 500gm thrice daily after meal Lavangadi vati - 500mg thrice d

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals of either sex above the age of 15 years to 65 years. 2. Subjects testing positive for SARS CoV-2 by RT-PCR, presenting with no symptoms or mild symptoms (as defined by US-CDC). 3. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study

Exclusion criteria

Exclusion criteria: 1. Cases of COVID-19 with clinical severity ranging from moderate to critical (as defined by US-CDC). 2. Pregnant and Lactating females. 3. Subjects having uncontrolled and unstable co morbidities. 4. Immunocompromised subjects or those taking any kind of immunosuppressive therapy. 5. COVID-19 positive cases participating as subjects in other COVID-19 clinical trials. 6. Subjects having a past history of allergy to any medicine that is part of the Ayurvedic intervention. Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrolment or could interfere with his participation in, and completion of the protocol.

Design outcomes

Primary

Measure	Time frame
1) To assess the effectiveness of Ayurvedic fixed drug combination (Mahasudarshan ghana vati, Samsamani vati and Lavangadi vati) in preventing the progression of severity of the disease in SARS-CoV 2 tested positive asymptomatic and mild cases of COVID-19.Timepoint: 3 months	—

Secondary

Measure	Time frame
1) To assess changes in Quality of Life (QoL) of the subjects using WHO QOL-BREF scale. 2) To assess the safety of Ayurvedic drug combination by observing for adverse events. Timepoint: 3 MONTHS	—

Countries

India

Contacts

Public ContactDr Bishnu Choudhury

North Eastern Institute of ayurveda and homoeopathy

drbishnuchoudhury@gmail.com9401597062

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026